A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012 for Acute Bronchitis
Latest Information Update: 03 Feb 2022
At a glance
- Drugs DW-1601 (Primary)
- Indications Acute bronchitis
- Focus Registrational; Therapeutic Use
- Sponsors Daewon Pharmaceutical
Most Recent Events
- 14 Feb 2020 New trial record